Search for a trial

Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.

Primary objective: to explore 18F-FDHT PET/CT as a predictor of response in patients with metastasized CRPC to be treated with enzalutamide. Secondary objective: to explore 18F-FDHT PET/CT as a predictor of clinical survival endpoints in patients…

A phase I study of high-dose, intermittent sunitinib in patients with solid tumors

Primary objectives:- To determine the maximum tolerated dose (MTD) of sunitinib when administered once a week or once every two weeks.- To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule- To…

Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases form wild type KRAS colorectal cancer. EORTC 40091.

Primary objective: to detect an increase in progression free survival (PFS*, see chapter 7.3.6) rate at 1 year in each experimental arm (mFOLFOX6 + bevacizumab or panitumumab) compared to mFOLFOX6 alone arm as perioperative treatment for resectable…

[18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer

Primary Objective: the primary objective of this study is to determine the feasibility of [18F]FDHT PET/CT for in vivo evaluation of bone metastases in prostate cancer. Active locations will be compared with those seen on conventional imaging (bone…

Protocol to obtain tumor biopsies from patients with locally advanced (incurable) or metastatic cancer to improve selection for clinical trials.

* To stratify cancer patients for participation in clinical trials.

An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer

To explore the effect of Eligard® on the following prostate cancer biomarkers:• Testosterone in serum• Prostate Specific Antigen (PSA) in serum• Prostate Cancer Antigen (PCA3 score) in urine • PSA mRNA in blood/PBMC• PCA3 mRNA in blood/PBMC• TMPRSS2…

Pilot study: The use of PET-MRI in the follow-up of RFA treated colorectal liver metastases

The primary objective of this study is to evaluate the ability of PET-MRI to detect LSR during the first year of follow-up after RFA treatment of CRLM as compared with ceCT and PET-CT. Standard reference will be histology (when available) or…

Fase I/II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating irresectable liver metastases

Primary objective * To determine the overall response rate of two PHP with an interval of at least 6 weeks and 3 mg/kg melphalan in irresectable liver metastases patients.* To determine the percentage of patients qualifying for resection. Secondary…

Optimization of systemic treatment strategies in elderly patients with advanced solid malignancies: OptiMal trial

To assess whether the presence of a myelodysplastic syndrome, idiopathic cytopenia of undetermined significance (ICUS) or idiopathic dysplasia of undetermined significance (IDUS), correlates with treatment intensity and clinical outcome in older…

Phase I/II study with the combination of dacomitinib and PD-0325901 in metastatic KRAS mutation positive non-small cell lung cancer

Primary objectivesPhase I:To determine the recommended phase 2 dose (RP2D) of the dacomitinib-PD-0325901 combination in patients with KRASm NSCLC Phase II:To determine the progression free survival of the dacomitinib/PD-0325901 combination compared…